Repligen (NASDAQ:RGEN) Stock Falls 6.4% – Here’s Why

Repligen Corporation (NASDAQ:RGEN) fell 6.4% on Thursday. The stock traded as low as $180.05 and last traded at $179.9820. 656,256 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 1,020,536 shares. The stock had previously closed at $192.23.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wells Fargo & Company raised their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. HSBC reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $168.57.

Repligen Trading Down 6.5%

The stock has a market cap of $10.15 billion, a PE ratio of 246.26, a PEG ratio of 3.55 and a beta of 1.05. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The firm has a fifty day simple moving average of $168.59 and a two-hundred day simple moving average of $140.59.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the prior year, the business earned $0.26 earnings per share. Repligen’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities analysts expect that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Institutional Trading of Repligen

A number of hedge funds have recently made changes to their positions in RGEN. United Capital Financial Advisors LLC purchased a new position in shares of Repligen during the 2nd quarter valued at about $380,756,000. Maverick Capital Ltd. purchased a new stake in Repligen in the first quarter worth approximately $178,946,000. Wasatch Advisors LP bought a new position in Repligen during the first quarter valued at approximately $146,513,000. William Blair Investment Management LLC bought a new position in Repligen during the second quarter valued at approximately $107,593,000. Finally, Bamco Inc. NY purchased a new position in shares of Repligen during the second quarter worth approximately $102,121,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.